Comparison of the clinical application of rabeprazole and omeprazole in the treatment of Hp positive peptic ulcer with bleeding
Objective:To compare and analyze the clinical effects of rabeprazole and omeprazole in the treatment of Hp positive peptic ulcer with bleeding.Methods:The clinical data of 112 HP-positive peptic ulcer patients with bleeding treated in our hospital from February 2022 to August 2023 were retrospectively collected.Conventional drugs,according to different treatment,the patients can be divided into rabeprazole azole groups(rabeprazole azole treatment,n=57)and omeprazole group(omeprazole treatment,n=55).8 weeks after treatment compared two groups of clinical curative effect,clinical symptoms,the psychological health status and Hp eradication rate.Results:After treatment,the overall effective rate of treatment in the rabeprazole group was significantly higher than that in the omeprazole group(89.09%)(P<0.05);after treatment,the Hp eradication rate in the rabeprazole group was significantly higher than that in the omeprazole group(P<0.05);The nine symptom scores for somatic,anxiety,depression,and interpersonal sensitivity were significantly lower in the rabeprazole group than in the omeprazole group(p<0.05);The rate of relief of abdominal distension and abdominal pain after treatment was significantly higher in the rabeprazole group than in the omeprazole group;the number of belches and the area of remaining ulcers were significantly lower than in the omeprazole group(P<0.05).Conclusion:Compared with omeprazole,rabeprazole is more clinically effective in treating patients with Hp-positive peptic ulcer with bleeding,more conducive to improving patients'clinical symptoms and mental health status,and improving the Hp eradication rate.
RabeprazoleOmeprazoleHelicobacter pylori positivityPeptic ulcer with bleedingClinical efficacy
万方数据
维普
